The Regulatory Framework

No regulation mandates "beagles" by name. The requirement is for a "non-rodent species." But the system is structured so that dogs — and specifically beagles — are the overwhelming default. Understanding why requires understanding the regulatory architecture.

The Two-Species Rule

For most drug programs, the internationally harmonized expectation (ICH M3(R2), finalized 2009) calls for safety data from two mammalian species before human clinical trials:¹

• One rodent (typically rat)
• One non-rodent (typically dog)

This is not a statute. It is regulatory guidance adopted by the FDA, EMA, and regulators worldwide. Deviating from it requires scientific justification — a burden most sponsors avoid.

Where Beagles Are Named

Regulatory documents rarely mandate "beagle" by name, but two key test guidelines come close:

• OECD Test Guideline 409 (1998) — Repeated Dose 90-Day Oral Toxicity Study in Non-Rodents. Directly states "the commonly used non-rodent species is the dog" and that "beagles are frequently used." Specifies minimum group sizes of >=4/sex/group.²
• U.S. EPA OPPTS 870.3150 — similarly states dogs are the commonly used non-rodent species, "preferably a defined breed, with beagles explicitly referenced."³

For some FDA-regulated products (food ingredients, additives), guidance frames long-term non-rodent studies as "usually dogs," recommends specific group sizes, and suggests starting age of ~4-6 months.⁴

The Feedback Loop

Beagle dominance is self-reinforcing through a four-step cycle:

1. 1.Guidelines reference dogs → sponsors design programs around dogs
2. 2.Sponsors use beagles → data accumulates in regulatory files
3. 3.Reviewers expect dog data → unfamiliar species raise questions, delays, risk
4. 4.Historical controls accumulate → new data is comparable only to prior beagle data

Each cycle makes switching harder. A company that proposed minipig data instead of dog data faces reviewer questions, potential clinical holds, and competitive disadvantage — even though the regulations technically permit it.

The US Framework

• Animal Welfare Act (1966) — the baseline federal law governing laboratory animal care. Sets minimum housing, exercise, and veterinary care standards. Critically, it excludes rats, mice, and birds — the most-used research animals.
• USDA APHIS — administers AWA licensing and inspection. Class A (breeders), Class B (dealers, nearly eliminated), Class C (exhibitors).
• Inspection concerns — at Ridglan Farms, the same USDA inspector conducted all 28 inspections over years.⁵

The EU Framework

• EU Directive 2010/63/EU — broader than AWA. Covers the breeding supply chain, not just research use. Requires authorization and registration. Mandates minimum unannounced inspection floors.
• ALURES database — EU-wide statistical reporting from 2018 onward. More granular than USDA data on procedure types and severity.
• EU single housing limited to 4 hours — a standard that does not exist in US regulation.⁶

Read the full comparison →

What Changed

The FDA Modernization Act 2.0 (December 2022) removed the 1938 mandate requiring animal testing for every new drug. It allows sponsors to use alternative methods — organ-on-chip, in silico, organoids — to support drug applications.

But the law makes animal testing optional, not prohibited. And the practical impact has been slow: most companies continue using animal models because the regulatory pathway is familiar, reviewers expect it, and the risk of rejection feels higher with new methods.

In April 2025, the FDA announced plans to make animal studies "the exception rather than the norm" within 3-5 years — starting with monoclonal antibodies.⁷

Sources

1. 1.ICH M3(R2) (2009). Nonclinical safety studies to support human clinical trials and marketing authorization.
2. 2.OECD Test Guideline 409 (1998). "The commonly used non-rodent species is the dog... beagles are frequently used."
3. 3.EPA OPPTS 870.3150. Dogs as commonly used non-rodent species.
4. 4.Preclinical Rationale. FDA guidance for food ingredient/additive toxicology: "usually dogs," starting age ~4-6 months.
5. 5.Data from Ridglan investigation. Same USDA VMO (Scott Welch) conducted all 28 inspections.
6. 6.Breeding Protocols. EU Directive 2010/63/EU Annex III: single housing "not more than 4 hours."
7. 7.FDA press announcement, April 2025. Roadmap to reducing animal testing in preclinical safety studies.